# US 2015/0306213 A1 · Hmgb1-derived peptides enhance immune response to antigens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0306213 A1
- Document ID: US20150306213A1
- Status: Published application
- Kind: A1
- Application number: 14/642,527
- Filed: 2015-03-09
- Published: 2015-10-29
- Earliest claimed: 2010-07-27
- Assignees: The Regents of the University of California
- Inventors: Davorka Messmer; Rebecca Saenz
- Web page: https://patentgrep.com/patent/US20150306213A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 39/0011: {Cancer antigens}
- A61K 40/10: characterised by the cell type used
- A61K 40/42: Cancer antigens
- A61P 37/02: Immunomodulators
- C07K 7/06: having 5 to 11 amino acids
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/575: {humoral response}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides an immunostimulatory peptide containing the amino acid sequence SAFFLFCSE and uses thereof. The invention also provides an immunostimulatory peptide containing the amino acid sequence DPNAPKRPPSAFFLX1X2X3X4 or derivatives thereof. In one embodiment, when X1 is alanine (A), glycine (G), or valine (V) then X2 is C, X3 is S and X4 is E; wherein when X2 is alanine (A), glycine (G), or valine (V) then X1 is F, X3 is S and X4 is E; wherein when X3 is alanine (A), glycine (G), or valine (V) then X1 is F, X2 is C and X4 is E; or wherein when X4 is alanine (A), glycine (G), or valine (V) then X1 is F, X2 is C and X3 is S.

## Claims

### Claim 1

An immunostimulatory peptide consisting of the amino acid sequence SAFFLFCSE (SEQ ID No:1).

### Claim at position 2

2-10. (canceled)

### Claim 11 (depends on 1)

The immunostimulatory peptide of claim 1 joined to a tag or crosslinking agent.

### Claim 12 (depends on 11)

The immunostimulatory peptide of claim 11, wherein the tag or crosslinking agent is selected from a group consisting of polyalkylene glycol (PAG) and a lipid.

### Claim 13 (depends on 12)

The immunostimulatory peptide of claim 12, wherein the PAG is a polyethylene glycol (PEG).

### Claim 14 (depends on 1)

The immunostimulatory peptide of claim 1 wherein the immunostimulatory peptide or derivative thereof is monomeric, dimeric, trimeric, or tetrameric.

### Claim 15 (depends on 21)

The immunostimulatory peptide of claim 21, wherein the derivative exhibits an alpha helix conformation.

### Claim 16 (depends on 15)

The immunostimulatory peptide of claim 15, wherein the alpha helix conformation provides a circular dichroism profile that shows negative peaks at about 205-206 nm or 222 nm.

### Claim 17 (depends on 15)

The immunostimulatory peptide of claim 15, wherein the alpha helix conformation provides a circular dichroism profile that shows a positive peak below about 200 nm.

### Claim at position 10

18-31. (canceled)

### Claim 32 (depends on 1)

A method of enhancing an immune response in a subject comprising administering a sufficient amount of the immunostimulatory peptide of claim 1 thereby enhancing the immune response in the subject.

### Claim 33 (depends on 1)

A method for selectively eliciting a cell-mediated immune response but not a humoral immune response in a subject comprising administering a sufficient amount of the immunostimulatory peptide of claim 1 thereby enhancing the cell-mediated immune response in the subject.

### Claim 34 (depends on 1)

A method for selectively eliciting a cell-mediated immune response and a humoral immune response in a subject comprising administering a sufficient amount of the immunostimulatory peptide of claim 1 thereby enhancing the cell-mediated immune response and a humoral immune response in the subject.

### Claim at position 14

35-50. (canceled)
